Does a higher dose of Mounjaro produce better results?

What the trial data actually show about dose and weight loss

The SURMOUNT-1 trial enrolled 2,539 adults with obesity and no diabetes, comparing tirzepatide at 5mg, 10mg and 15mg against placebo over 72 weeks. Average body-weight reductions were roughly 15%, 19.5% and 20–21% at those three maintenance doses respectively. The direction is clear: moving higher on the schedule is associated with greater average loss.

What that table of numbers doesn't capture is the spread. Some people at 5mg exceeded the 10mg average; some at 15mg fell short of 20%. If you want to understand whether 5mg of Mounjaro actually delivers meaningful results, the answer depends on more than the trial averages alone. Tirzepatide works through two gut-hormone receptors simultaneously, a dual GIP and GLP-1 mechanism that is more nuanced than a simple dose-equals-outcome equation. Your metabolic starting point, how your gut motility responds, and how well you manage the lifestyle changes alongside treatment all shape where you land. Our page on whether 5mg Mounjaro works better than 2.5mg looks at how that step up compares in practice, drawing on the same trial data. The NICE appraisal of tirzepatide (TA1026) notes that results at the highest tolerated dose, rather than necessarily the highest available dose, are what the clinical review looks at.

The practical takeaway: more dose can mean more effect, but the ceiling matters less than reaching your highest tolerated dose safely.

Why the titration schedule exists, and what happens at each step

Mounjaro's licensed schedule in the UK starts at 2.5mg. That first pen's purpose is adjustment, not weight loss, and our page on how well 2.5mg Mounjaro works explains what you can realistically expect during those opening weeks. GLP-1-pathway medicines slow gastric emptying and reduce appetite sharply in many people; starting low keeps nausea and vomiting manageable while your digestive system adapts. UK strengths run 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg, typically stepped up by a prescriber in four-week intervals.

A question our prescribers hear regularly is whether skipping a step would accelerate progress. The evidence doesn't support that. Jumping dose increments increases the likelihood of side effects significant enough to force a step back down, which loses time rather than saving it. Steady progression also helps identify the dose where your appetite suppression stabilises, for some people that is 7.5mg or 10mg, not 15mg, and there is no clinical advantage in pushing further if progress is already strong.

If you're looking at what the shift from the first pen to subsequent doses actually looks like in practice, our page on whether 5mg Mounjaro is better than 2.5mg covers that specific step in detail. The broader dose progression picture, including what prescribers look for before approving an increase, is explored on our Mounjaro higher dose page.

When a prescriber might not increase your dose

Dose increases are not automatic. A clinical review happens before every step up, which is one reason NICE's guidance flags that continuing treatment should be reassessed if less than 5% weight loss has been achieved at the highest tolerated dose after six months. That threshold works in both directions: if you're losing weight steadily at 10mg and tolerating it well, there may be no reason to push to 12.5mg at all.

Side effects are the other consideration. Nausea, loose stools, reflux and fatigue are the most commonly reported, and they tend to resurface briefly at each dose increase before settling. Most people find this manageable. For a small number, side effects at a given dose remain persistent enough that staying at the previous level makes more sense clinically. The NHS tirzepatide medicines page lists the full side-effect profile and the signs that need prompt medical attention.

Certain situations also prompt a prescriber to pause or slow the schedule: recent surgery, significant illness, very low food intake, or a need to manage medicines that interact with slower gastric transit. The contraception note is worth flagging specifically: oral contraceptives may be absorbed less reliably during the first four weeks of treatment and after each dose increase, so additional contraception is recommended during those windows for women taking the pill. Your prescriber will go through this at each review.

Choosing the right route to reach the dose that works for you

The NHS route to Mounjaro has phased eligibility criteria that many people don't currently meet, and waiting times vary considerably by area. Private treatment through a regulated online pharmacy offers a structured alternative: a consultation that is clinically reviewed by a named prescriber, dose increases approved only when the evidence supports them, and repeat supplies dispatched once approved.

For context on what private treatment costs and what that price typically includes, our treatment and pricing page sets it out plainly. There are no subscriptions and no hidden fees, every repeat order goes through the same clinical review before anything ships.

The practical experience: once approved, your Mounjaro pen arrives via DPD the next working day in plain, unbranded packaging, with tracking on your phone from the moment it leaves our pharmacy. What matters most, though, happens before dispatch, a real prescriber reading your answers and deciding whether an increase is right at this point, not a form routed through an algorithm.

If you'd like a prescriber to review where you are in the schedule and whether your next step makes clinical sense, you're welcome to speak to our prescribers through a free consultation.